{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:03:04Z","timestamp":1769166184913,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancerepidemiology.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.canep.2015.04.005","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T17:30:11Z","timestamp":1429983011000},"page":"307-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Annie","family":"Gu\u00e9rin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medha","family":"Sasane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Macalalad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Galebach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kageleiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Culver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.canep.2015.04.005_bib0105","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"August (7153)","key":"10.1016\/j.canep.2015.04.005_bib0110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"June (25)","key":"10.1016\/j.canep.2015.04.005_bib0115","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canep.2015.04.005_bib0120","unstructured":"http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm376058.htm. Accessed 5\/14\/2014."},{"issue":"suppl; abstr 8002","key":"10.1016\/j.canep.2015.04.005_bib0125","first-page":"5s","article-title":"First-line crizotinib versus pemetrexed \u2013 cisplatin or pemetrexed \u2013 carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)","volume":"32","author":"Mok","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canep.2015.04.005_bib0130","unstructured":"Zykadia (ceritinib) Capsules, oral [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014."},{"issue":"July (13)","key":"10.1016\/j.canep.2015.04.005_bib0135","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"August (8)","key":"10.1016\/j.canep.2015.04.005_bib0140","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.humpath.2009.01.012","article-title":"Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas","volume":"40","author":"Boland","year":"2009","journal-title":"Hum Pathol"},{"issue":"September (26)","key":"10.1016\/j.canep.2015.04.005_bib0145","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"issue":"March (3)","key":"10.1016\/j.canep.2015.04.005_bib0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1593\/neo.07878","article-title":"EML4-ALK fusion lung cancer: a rare acquired event","volume":"10","author":"Perner","year":"2008","journal-title":"Neoplasia"},{"issue":"October (20)","key":"10.1016\/j.canep.2015.04.005_bib0155","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-08-1018","article-title":"Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts","volume":"14","author":"Takeuchi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"April (8)","key":"10.1016\/j.canep.2015.04.005_bib0160","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"issue":"January (1)","key":"10.1016\/j.canep.2015.04.005_bib0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JTO.0b013e31815e8b60","article-title":"EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers","volume":"3","author":"Inamura","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canep.2015.04.005_bib0170","series-title":"Xalkori (crizotinib) Capsules, oral [prescribing information]","year":"2013"},{"issue":"May (9)","key":"10.1016\/j.canep.2015.04.005_bib0175","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2015.04.005_bib0180","unstructured":"http:\/\/www.fda.gov\/MedicalDevices\/ProductsandMedicalProcedures\/DeviceApprovalsandClearances\/Recently-ApprovedDevices\/ucm270832.htm. Accessed 5\/15\/2014."},{"issue":"January (1)","key":"10.1016\/j.canep.2015.04.005_bib0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e318274a83e","article-title":"Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent","volume":"8","author":"Conklin","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"July (7)","key":"10.1016\/j.canep.2015.04.005_bib0190","doi-asserted-by":"crossref","first-page":"796","DOI":"10.5858\/arpa.2011-0321-OA","volume":"136","author":"Wallander","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.canep.2015.04.005_bib0195","series-title":"NCCN clinical practice guidelines in oncology: non-small cell lung cancer version 3.2014","year":"2014"},{"issue":"January (1 Suppl.)","key":"10.1016\/j.canep.2015.04.005_bib0200","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1378\/chest.123.1_suppl.21S","article-title":"Epidemiology of lung cancer","volume":"123","author":"Alberg","year":"2003","journal-title":"Chest"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782115000879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782115000879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T06:26:40Z","timestamp":1537684000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782115000879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1877782115000879"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2015.04.005","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2015.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}